"Those with the highest burden of comorbidity had over a 30% increased risk of having disability worsening," Salter said. "In ...

Women had a lower probability of receiving any disease-modifying treatment (DMT) and were even less likely to get ...

A study presented at ECTRIMS 2024 has identified critical biomarkers that can predict disability worsening in multiple ...

Sanofi’s experimental drug for a form of multiple sclerosis delayed the progression of disability by nearly a third, ...

Novartis' new data for Kesimpta showed reduced disability progression in relapsing multiple sclerosis patients. Continuous ...

A study has uncovered novel ancestry-specific genetic variants linked to multiple sclerosis (MS), offering new insights that ...

Researchers have identified biomarkers that can predict disease progression in multiple sclerosis, which could lead to the ...

Available disease-modifying therapies can prevent relapses and relapse-associated worsening in people with multiple sclerosis by targeting autoimmunity through various mechanisms. However, these ...

Tolebrutinib delayed the onset of disability progression by 31% for patients with a type of the disease called non-relapsing ...

Sanofi has shared data from the phase 3 HERCULES trial that could rescue its multiple sclerosis (MS) drug candidate ...

Sanofi reports positive phase 3 HERCULES study data for tolebrutinib in non-relapsing secondary progressive multiple sclerosis, showing a 31% delay in disability progression. Study also revealed ...

When it comes to living with Multiple Sclerosis, community is everything. That's why one organization is holding a fundraiser ...